Roche (OTCMKTS:RHHBY) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Roche (OTCMKTS:RHHBY) from a strong sell rating to a hold rating in a research report released on Monday morning,Zacks.com reports.

RHHBY has been the subject of several other research reports. HSBC lowered shares of Roche from a “buy” rating to a “hold” rating in a research note on Monday, July 6th. Morgan Stanley raised Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price for the company in a research report on Friday, August 7th. Five analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $60.00.

Roche Stock Up 1.7%

OTCMKTS RHHBY opened at $58.47 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72. Roche has a one year low of $39.50 and a one year high of $60.85. The business’s fifty day moving average is $53.58 and its 200-day moving average is $52.95.

Institutional Investors Weigh In On Roche

Several institutional investors have recently made changes to their positions in RHHBY. McIlrath & Eck LLC purchased a new position in shares of Roche in the first quarter valued at $39,000. Oakworth Capital Inc. lifted its holdings in Roche by 20.8% during the 4th quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock worth $86,000 after purchasing an additional 285 shares in the last quarter. Atlas Capital Advisors Inc. bought a new position in Roche in the 4th quarter worth about $192,000. Pinnacle Wealth Management Advisory Group LLC purchased a new position in Roche during the 1st quarter valued at about $208,000. Finally, Renasant Bank purchased a new position in Roche during the 2nd quarter valued at about $210,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.